Rate of Hearing Loss in Platinum‐Naïve Patients Receiving Immune Checkpoint Inhibitors
A significant proportion of our monitored platinum-naïve ICI patients met hearing-loss criteria. Prospective studies with standardized audiologic surveillance are needed to further quantify the true incidence of ICI ototoxicity.
Authors
- Paul W. Gidley (ORCID: https://orcid.org/0000-0003-3706-8781)
- Gabriel Gidley (ORCID: https://orcid.org/0000-0002-1260-5395)
- Dianna Roberts (ORCID: https://orcid.org/0000-0003-1414-1878)
- Shirin Jivani
- Kaitlyn A. Brooks (ORCID: https://orcid.org/0000-0001-5717-558X)
- Olivia Grimley
- Jack Phan
- Haitao Wang (ORCID: https://orcid.org/0000-0001-6910-974X)
- Marc‐Elie Nader
- Katherine Hutcheson
- Aung Naing
- Xin Wang (ORCID: https://orcid.org/0000-0003-0451-6293)
Institutions
- The University of Texas MD Anderson Cancer Center (US)
Publication Details
- Journal
- Otolaryngology
- Published
- 2026-03-07
- DOI
- https://doi.org/10.1002/ohn.70191
- Primary Topic
- Brain Metastases and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00